AI Science Tracker

AI-assisted virtual screening identifies a dual-stage antimalarial candidate

Federal University of Goiás · 16 Mar 2021 · medicine

Discovery

AI-assisted virtual screening identifies a dual-stage antimalarial candidate

An AI-assisted virtual-screening cascade using shape-based and machine-learning models prioritized potential Plasmodium kinase inhibitors. Eight virtual hits were experimentally evaluated; LabMol-167 inhibited P. berghei ookinete conversion and P. falciparum blood-stage parasites at nanomolar concentrations and showed low cytotoxicity in mammalian cells. A possible additional PK5 target was proposed from computational target fishing and docking, not demonstrated experimentally. This is a preclinical hit result and does not establish therapeutic efficacy. The article appeared online on 2021-03-16.

Technology: AI-assisted virtual screening combining shape-based and machine-learning models

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Eight virtual hits were evaluated; LabMol-167 showed nanomolar activity in P. berghei ookinete conversion and P. falciparum blood-stage assays, with low mammalian-cell cytotoxicity.
  • Still unknown: The PK5 dual-target mechanism is proposed from computational target fishing and docking; in-vivo efficacy and clinical benefit are not established.
  • AI role: Shape-based and machine-learning virtual screening prioritized candidates for experimental evaluation; the abstract explicitly links the integrated AI-assisted screen to this candidate-identification workflow.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/33247522/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 17 Nov 2026. Review scope: Primary PubMed abstract, publication metadata, and author-affiliation block; claim limited to the findings explicitly stated in the abstract..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.